Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study.
Zopiclone, like zolpidem, is under surveillance in France due to its potential for dependence, abuse and misuse. However, part of the narcotics regulation was implemented in 2017 in France for zolpidem only, which has led to an increase in the number of zopiclone consumers. The objective of this art...
| Publicado en: | International Journal of Mental Health & Addiction Vol. 22; no. 6; pp. 3733 - 3748 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Artículo |
| Publicado: |
Springer Nature
Dec2024
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=181829868&site=ehost-live header: @attributes: shortDbName: ssf uiTerm: 181829868 longDbName: Social Sciences Full Text (H.W. Wilson) uiTag: AN controlInfo: bkinfo: jinfo: jid: 15571874 46AW jtl: International Journal of Mental Health & Addiction issn: 15571874 maglogo: N pubinfo: dt: Dec2024 vid: 22 iid: 6 pid: 237 pub: Springer Nature artinfo: ui: 181829868 10.1007/s11469-023-01078-y ppf: 3733 ppct: 15 formats: fmt: – @attributes: type: T – @attributes: type: P size: 983KB tig: atl: Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study. aug: au: Aquizerate, Aurélie Laforgue, Edouard-Jules Istvan, Marion Rousselet, Morgane Gérardin, Marie Jouanjus, Emilie Libert, Frédéric Caous, Anne-Sylvie Djezzar, Samira Boucher, Alexandra Daveluy, Amélie Eiden, Céline Fauconneau, Bernard Fournier-Choma, Christine Gibaja, Valérie Lacroix, Clémence Lapeyre-Mestre, Maryse Le Boisselier, Reynald Revol, Bruno Guerlais, Marylène affil: https://ror.org/03gnr7b55 Nantes Université, CHU Nantes, Centre d'Evaluation Et d'Information Sur La Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, 9 Quai Moncousu, 44000, Nantes, France INSERM U1246 SPHERE "methods in Patient-Centered Outcomes and Health Research", Nantes and Tours University, Nantes, France https://ror.org/017h5q109 Centre for Evaluation and Information On Pharmacodependence, Clinical Pharmacology Department, Toulouse University Hospital, Toulouse, France https://ror.org/02tcf7a68 Centre for Evaluation and Information On Pharmacodependence, Clinical Pharmacology Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France su: Medical personnel Drug addiction Fraud Drug abuse Zolpidem sug: subj: Medical personnel Drug addiction Fraud Drug abuse Zolpidem keyword: Abuse Addictovigilance Dependence Hypnotics Misuse Sedatives Zopiclone Abuse Addictovigilance Dependence Hypnotics Misuse Sedatives Zopiclone ab: Zopiclone, like zolpidem, is under surveillance in France due to its potential for dependence, abuse and misuse. However, part of the narcotics regulation was implemented in 2017 in France for zolpidem only, which has led to an increase in the number of zopiclone consumers. The objective of this article is to present French addictovigilance data regarding the evolution of the abuse, dependence and misuse profiles of zopiclone. We used the following 3 data sources over two periods: the 3-year period before the regulatory measure regarding zolpidem (2014–2016) and the 3-year period after the regulatory measure (2018–2020): (i) Medic'AM, a public database which provides a good overview of the number of boxes of zopiclone reimbursed in France; (ii) all French cases of drug dependence or abuse reported by health professionals to the French Addictovigilance Network (FAN); and (iii) a national epidemiological tool based on the surveillance of falsified prescriptions. Between the first and the second study periods (i) despite an increase in the exposure of the population to zopiclone, the proportion of reports to the FAN remained stable; (ii) the proportion of misusers increased significantly (p < 0.01), from 27% (n = 31) to 48.3% (n = 72); (iii) the profile of problematic users remained comparable with persistence of markers of problematic use; and (iv) there was a significant increase (p = 0.01) in zopiclone fraud for obtention, from 26.1% (n = 30) to 40.9% (n = 61), which mainly concerned nomadism. Prescribers should remain cautious in providing zopiclone prescriptions. pubtype: Academic Journal doctype: Article src: R language: English refInfo: copyright: @attributes: flag: N holdings: @attributes: islocal: N |
|---|